Cancer Patient in Remission Three Years after Stem Cell Implant of Immune Response
The MAGE-A3 vaccine used in this study is manufactured by Glaxo-Smith-Kline, and is currently showing promise in Phase III trials in small cell lung cancer, the researchers said.
This entry was posted on Monday, November 26th, 2007 at 4:13 pm and is filed under Research, Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.